TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing diagnostic upper endoscopy in our endoscopic room were enrolled.~Exclusion Criteria:~* A therapeutic upper endoscopic procedure, sedated endoscopy, contraindication to Buscopan (hyoscine N-butylbromide)~* Allergy to meperidine~* American Society of Anesthesiology (ASA) risk Class 3 or higher~* Renal failure~* Decompensated cirrhosis~* Aged less than 20 years or more than 65 years~* Pregnancy~* Refusal to provide written informed consent.

- Gender: None
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- meperidine (Type: EXPERIMENTAL): 25 mg of meperidine is injected intramuscularly before EGD
- placebo (Type: PLACEBO_COMPARATOR): placebo was given intramuscularly before EGD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet the DSM-IV criteria for primary degenerative dementia~* Meet standard clinical criteria for frontotemporal dementia (ie., frontotemporal degeneration including both the frontal/behavioural variant and primary progressive aphasia)~* Have significant behavioural problems as demonstrated by a score of at least eight on the Neuropsychiatric Inventory (NPI) an~* An independent clinical decision to receive psychotropic medication for behavioural disorders~Exclusion Criteria:~* An abnormal biochemical screening (blood cell count, vitamin B12 or thyroid function tests)~* Significant medical illness or other medical/neurological conditions which diminish cognitive function (including: drug overdose, severely disturbed liver, kidney, lung or heart function, anemia, hypothyroidism, vitamin B12 or folic acid deficiency, syphilis, uncontrolled diabetes, Parkinson's disease, Huntington's chorea, progressive supranuclear paralysis, brain tumour, subdural hematoma, multiple sclerosis, or brain trauma);~* An Hachinski ischemic score ≥444;~* Electrocardiographic, laboratory or physical evidence of significant cardiovascular disease;~* Hypertension \>160 mmHg systolic or \>100 mmHg diastolic;~* A brain computed tomographic scan that could not be interpreted as consistent with FTLD;~* Presence of premorbid or current psychiatric diagnosis (including: major depression, schizophrenia, psychotic symptoms of a severity likely to provoke violent or dangerous behaviour such as command hallucinations to harm people or persecutory delusions that provoke violent reactions, psychoactive substance abuse or dependence);~* Contraindications to receiving citalopram (such as concomitant MAOI or within 2 weeks, or hypersensitivity to citalopram); or~* Ongoing need for psychotropic medications (i.e., unsuitable for washout) or administration of a depot antipsychotic injection within one treatment cycle of visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 19 years~* ≥ 6 months since the last stroke~* ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 point at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)~* Informed consent has been obtained~Exclusion Criteria:~* Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis~* History(within 4 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb~* History(within 4 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb~* Fixed joint/muscle contracture~* Severe atrophy~* Concurrent treatment with an intrathecal baclofen~* Patients who have bleeding tendency or taking anti-coagulant~* Dysphagia and Breathing Difficulties~* History(within 4 months of screening visit) Planned(during study period) treatment with Botulinum Toxin~* Known allergy or sensitivity to study medication or its components~* Concurrent or planed Muscle relaxants and/or benzodiazepine medication If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.~* Current Physical, occupational, Splinting therapy These therapy regimens will be permitted if they have been stable in the one month before screening; no treatment and no changes are planned during the study.~* Patient who are participating in other clinical trials at the screening~* Females who are pregnant, breastfeeding, or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of contraception.~* Patients who are not eligible for this study at the discretion of the investigator.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CORETOX® (Type: EXPERIMENTAL): None
- BOTOX® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Treatment Success of Botox Injection in the Internal Sphincter Versus Isosorbidedinitrate Ointment in Patients With an Anal Fissure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all consecutive patients over the age of 18 with a chronic anal fissure presenting to our surgical outpatient clinic~Exclusion Criteria:~* pregnancy~* previous anal surgery~* Crohn's disease~* systemic causes of an anal fissure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botox injection (Type: EXPERIMENTAL): injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
- ISDN ointment (Type: ACTIVE_COMPARATOR): application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Standard-risk ALL~* Achieving CR1~* Undergoing HLA-matched allo-HSCT (related or unrelated)~Exclusion Criteria:~* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)~* Patients with any conditions not suitable for the trial (investigators' decision)

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BUCY (Type: EXPERIMENTAL): For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
- TBICY (Type: ACTIVE_COMPARATOR): For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Mixed Working Memory Training on Subsequent Training Gains Among Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Native English speakers or acquisition of English before age 6 yrs old~* Self-report of hearing ability sufficient to engage with lab personnel~* No stroke in the last 3 years~* No current cancer treatment involving radiation or chemotherapy - No self-reported learning disability~* No self-reported psychiatric disorder~* Willingness to be randomly assigned to training conditions~* No plans that would limit participation during the activity period~* No participation in a cognitive intervention program in the last year~No additional Exclusion Criteria.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Different Mixed Condition (DM) (Type: EXPERIMENTAL): Training in both Lexical Decision Span and Category Span in Phase 1 (which are both different from the target task Reading Span in Phase 2).
- Different Single Condition (DS) (Type: EXPERIMENTAL): Training in the Lexical Decision Span in Phase 1 (which is different from the target task Reading Span in Phase 2).
- Same Task (ST) Practice Control (Type: ACTIVE_COMPARATOR): Training in Reading Span task in Phase 1 (which is the same as target task in Phase 2).
- Non-WM Placebo Control (PC) (Type: PLACEBO_COMPARATOR): Training in a speeded Lexical Decision task only (which has no memory component) in Phase 1 prior to Phase 2 training in WM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with iron deficiency anaemia as a consequence of CKD or IBD (on the basis of local definition or clinical judgement), treated on the doctor's discretion with Monofer® as standard treatment according to current practice~Exclusion Criteria:~* Patients diagnosed with both CKD and IBD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CKD, iron deficiency anaemia (Type: None): 10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
- IBD, iron deficiency anaemia (Type: None): 10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multinational Phase III Study of CS-8958 (MARVEL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of influenza~* Axillary temperature of \> or = to 37.5 degrees C~Exclusion Criteria:~* Infection by bacteria species and/or virus other than influenza virus~* Chronic respiratory disease~* Renal dysfunction

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-8958 Low Dose (Type: EXPERIMENTAL): CS-8958 powder to be inhaled - low-dose arm
- CS-8958 High Dose (Type: EXPERIMENTAL): CS-8958 powder to be inhaled - high-dose arm
- Oseltamivir phosphate (Type: ACTIVE_COMPARATOR): oseltamivir phosphate oral capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with lymphoid malignancies: CR1 or CR2 for acute lymphoblastic leukemia; T cell lymphoma (any CR/PR); B cell lymphoma (PR1 or CR2), hodgkin's disease (CR2 or beyond), Sezary syndrome~* patients with HLA matched sibling, unrelated (HLA 9\~10/10 matched) or haplo-identical donor~Exclusion Criteria:~* patients with active infection~* patients with abnormal liver function damage: ALT/AST above 2X normal range~* patients with abnormal renal function damage Scr\>160µmol/L;~* patients with insufficient pulmonary function (FEV1，FVC，DLCO\<50%）and heart failure or with EF \<50%)~* patients with mental instability~* unwilling to give inform consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PT-CY-FK +/- ATG (Type: EXPERIMENTAL): GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dissemination of a Theory-Based Bone Health Program in Online

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* being age 50 or older~* having access to the Internet and e-mail (at home or other places such as public~* libraries, computer lab, etc)~* being able to use the Internet/e-mail independently~* having an e-mail account (or being willing to obtain an e-mail account for this study)~* currently residing in a community setting in the United States~* being able to read and write English~Exclusion Criteria:~* are currently participating in any study(s) on: falls, osteoporosis, and /or nutrition~* had participated in our web-based hip fracture prevention conducted in 2006 - 2007

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TO-BoneHealth Group (Type: EXPERIMENTAL): The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
- TO-BoneHealth Plus Group (Type: EXPERIMENTAL): The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
- Control Group (Type: NO_INTERVENTION): No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Availability to attend clinic 6 days a week for approximately 30-60 minutes.~* Participants must fulfill DSM-IV criteria for opioid dependence. These criteria will be ascertained in the following manner: the physician will determine whether the individual is appropriate based on several clinical assessments that are routinely employed by methadone program physicians, including history and severity of opioid use, presence of track marks, prior treatment history, self-reported and/or observed signs and symptoms of opioid withdrawal. If any individual's degree of opioid dependence is questionable, that person will be excluded from further consideration as a participant.~* Participants must submit a urine negative for drugs of abuse other than opioids prior to starting the study.~Exclusion Criteria:~* Unstable medical condition or stable medical condition that would interact with study medications or participation.~* History of major psychiatric disorder (psychosis, schizophrenia, bipolar, depression)~* Pregnancy or plans to become pregnant or inadequate birth control (adequate birth control includes abstinence, condoms, birth control pills, etc).~* Present or recent use of over-the-counter psychoactive drug, prescription psychoactive drug or drug (including Maalox) that would have major interaction with drugs to be tested.~* Liver function tests greater than 3 times normal, BUN and Creatinine outside normal range, or thyroid function tests outside normal range.~* EKG abnormalities including but not limited to: bradycardia (\<60 bpm); prolonged QTc interval (\>450 msec); Wolff-Parkinson White syndrome; wide complex tachycardia; 2nd degree, Mobitz type II heart block; 3rd degree heart block; left or right bundle branch block.~* Physical dependence on alcohol or drugs other than opioids or tobacco (as determined by physician assessment).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin (Type: ACTIVE_COMPARATOR): Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
- Placebo (Type: PLACEBO_COMPARATOR): Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Phenylephrine vs. Norepinephrine Infusion Undergoing Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* a healthy singleton pregnancy scheduled for elective cesarean delivery (CD) under combined spinal-epidural anesthesia (CSEA),~* American Society of Anesthesiologists (ASA) physical status I/II~* 20 to 40 years old~Exclusion Criteria:~* history of mental disorder or epilepsy,~* tricyclic or imipramine antidepressant use,~* central nervous system (CNS) disease,~* preexisting or pregnancy-induced hypertension,~* lumbar injury,~* severe hypovolemia,~* allergy~* history of hypersensitivity to vasopressor~* body mass index (BMI) \>40 kg/m2,~* infection at the puncture site

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 Elements (Type: EXPERIMENTAL): Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
- Group 2 Elements (Type: EXPERIMENTAL): Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
- Group 3 Elements (Type: PLACEBO_COMPARATOR): In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has type 2 diabetes and is at least 18 years of age and no older than 78 years of age~* is male or is a female who is unlikely to conceive children~* is on stable doses of a peroxisome proliferator-activated receptor gamma agonist and metformin OR metformin and a sulfonylurea agent~Exclusion Criteria:~* has type 1 diabetes~* has taken a dipeptidyl peptidase (DPP-4) inhibitor or a glucagon-like peptide-1 (GLP-1) analogue~* is on a weight loss program that is not in the maintenance phase or has started a weight loss medication within 8 weeks of screening~* has had surgery within 30 days of screening or has major surgery planned during the study~* is on or is likely to require treatment with corticosteroids for more than 2 weeks~* has a history of active liver disease, including hepatitis B or C, cirrhosis, or gallbladder disease~* is human immunodeficiency virus (HIV) positive~* has congestive heart failure, or has had new or worsening symptoms of coronary heart disease within 3 months prior to screening~* has had acute coronary syndrome, coronary artery intervention, or stroke within 3 months of screening~* has severe active peripheral vascular disease~* has a history of cancer or blood disorder~* is pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100 mg tablet orally once daily for 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to sitagliptin orally once daily for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete